Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glimpse into the role of Kupffer cells in a spheroid model of metabolic dysfunction-associated steatohepatitis (MASH).

Biology open·2026
Same author

Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.

Cancer immunology, immunotherapy : CII·2026
Same author

exTra Mini-review Series on ECP in Transplantation.

Transplantation direct·2025
Same author

Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial.

The British journal of dermatology·2025
Same author

Soluble CD46 improves detection of hepatic steatosis by contrast-enhanced computed tomography before liver surgery.

International journal of surgery (London, England)·2025
Same author

Is operational tolerance induction finally safe and feasible for some kidney transplant recipients: A breakthrough to a new horizon?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025

Related Experiment Video

Updated: Apr 11, 2026

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination
08:52

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Published on: February 18, 2017

11.7K

First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation.

Yorick Soeder1, Martin Loss1, Christian L Johnson1

  • 1Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.

Stem Cells Translational Medicine
|June 5, 2015
PubMed
Summary

Multipotent adult progenitor cells (MAPCs) show promise for organ transplant patients, potentially reducing the need for immunosuppression. Early trials indicate MAPC infusions are safe and feasible, with no acute toxicity observed in the first patient.

Keywords:
Cell therapyImmunomodulationLiver transplantationMesenchymal stem cellsMultipotent stem cellsTolerance

More Related Videos

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

22.9K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination
08:52

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Published on: February 18, 2017

11.7K
Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

22.9K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K

Area of Science:

  • Regenerative Medicine
  • Transplantation Immunology
  • Cell Therapy

Background:

  • Mesenchymal stem cells and multipotent adult progenitor cells (MAPCs) are being explored as alternatives to pharmacological immunosuppression in solid organ transplantation.
  • Reducing immunosuppression can mitigate side effects and improve patient outcomes.

Purpose of the Study:

  • To assess the safety and feasibility of administering third-party MAPCs to a solid organ transplant recipient.
  • To evaluate the clinical course of the first patient in the MiSOT-I phase I trial.

Main Methods:

  • The study involved a single patient receiving a living-related liver graft.
  • The patient received one intraportal injection and one intravenous infusion of third-party MAPCs.
  • MAPC administration was performed under a low-dose pharmacological immunosuppressive regimen.

Main Results:

  • Cell administration via intraportal and intravenous routes was technically feasible.
  • No acute toxicity or adverse events were observed following MAPC infusions.
  • The patient's clinical course was monitored following cell therapy.

Conclusions:

  • Third-party MAPC administration appears to be a safe and feasible therapeutic strategy in the context of solid organ transplantation.
  • Further research is warranted to explore the efficacy of MAPCs in reducing immunosuppression and improving transplant outcomes.